Reagents and instruments for immunology, cell biology and molecular biology.
 
> Oxaliplatin [61825-94-3]

Oxaliplatin [61825-94-3]

Print Print
Please log in

Cat# HY-17371-100mg

Size : 100mg

Brand : MedChemExpress


Oxaliplatine est un inhibiteur de la synthèse d'ADN. Oxaliplatine provoque des dommages de réticulation de l'ADN, empêche la réplication et la transcription de l'ADN et provoque la mort cellulaire. Oxaliplatine inhibe les lignées cellulaires de mélanome humain C32 et G361 en fonction du temps avec des valeurs IC50 de 0,98 μM et 0,14 μM, respectivement. Oxaliplatine induit l'autophagie cellulaire.

Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research.

For research use only. We do not sell to patients.

Oxaliplatin Chemical Structure

Oxaliplatin Chemical Structure

CAS No. : 61825-94-3

This product is a controlled substance and not for sale in your territory.

Based on 93 publication(s) in Google Scholar

Other Forms of Oxaliplatin:

  • Oxaliplatin-d10 In-stock
  • (rel)-Oxaliplatin Get quote

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2019 Sep;25(9):1428-1441.  [Abstract]

    Quantification of CD3+IFN-γ+ T cells in lung lobes taken from urethane-induced primary lung cancer models (n = 5 mice for SD group, n = 6 mice for all the other groups). Three coronal sections containing five pulmonary lobes from each mouse near the maximal diameters are quantified. Each dot represents one view field. A representative result from two independent experiments is shown.
    Description

    Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research[1][2][3].

    IC50 & Target

    IC50: DNA synthesis[1]
    In Vitro

    Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis[1].
    ? Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC)[2].
    ? Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Oxaliplatin Related Antibodies

    Cell Viability Assay[1]

    Cell Line: HCC, HCCLM3 and Hep3B cells
    Concentration: 24, 48 and 72 hours
    Incubation Time: 2, 4, 8, 16, 32, 64 and 128 μM
    Result: Decreased cell viability in a dose- and time-dependent manner.

    Cell Cycle Analysis[1]

    Cell Line: HCCLM3 and Hep3B cells
    Concentration: 10 μM
    Incubation Time: 24 hours
    Result: Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells).

    Cell Cycle Analysis[1]

    Cell Line: HCCLM3 cells
    Concentration: 10 μM
    Incubation Time: 48 hours
    Result: Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax.
    In Vivo

    Oxaliplatin (5-10 mg/kg; i.p.; for 32 days; nude mice) inhibits tumor growth[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Nude mice[1]
    Dosage: 5 and 10 mg/kg
    Administration: Intraperitoneal injection; for 32 days
    Result: Reduced tumor volume in HCCLM3 tumor xenografts.
    Clinical Trial
    Molecular Weight

    397.29

    Formula

    C8H14N2O4Pt
    CAS No.

    61825-94-3
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O1)C(O[Pt]21[NH2][C@@H]3CCCC[C@H]3[NH2]2)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    H2O : 2.17 mg/mL (5.46 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Oxaliplatin's activity)

    DMF : 1.67 mg/mL (4.20 mM; Need ultrasonic; DMSO can inactivate Oxaliplatin's activity)

    Ethanol : < 1 mg/mL (insoluble; DMSO can inactivate Oxaliplatin's activity)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.5171 mL 12.5853 mL 25.1705 mL
    5 mM 0.5034 mL 2.5171 mL 5.0341 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 1.92 mg/mL (4.83 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    • Protocol 2

      Add each solvent one by one:  5% w/v Glucose Solution

      Solubility: 3.33 mg/mL (8.38 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.57%

    COA (253 KB) HNMR (215 KB) LCMS (348 KB) Elemental Analysis Report (110 KB)

    Handling Instructions (2659 KB)
    References

    • [1]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71.  [Content Brief]

      [2]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11(10):859-63.  [Content Brief]

      [3]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6.  [Content Brief]

      [4]. Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604  [Content Brief]

      [5]. Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. Biomed Pharmacother. 1989;43(4):237-50.  [Content Brief]

      [6]. Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.  [Content Brief]

      [7]. Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11987-92.  [Content Brief]

      [8]. Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10):1433-40.  [Content Brief]

      [9]. Garrett MJ, et, al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMF / H2O 1 mM 2.5171 mL 12.5853 mL 25.1705 mL 62.9263 mL
    H2O 5 mM 0.5034 mL 2.5171 mL 5.0341 mL 12.5853 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Oxaliplatin Related Classifications

    Help & FAQs

    Keywords:

    Oxaliplatin61825-94-3DNA/RNA SynthesisApoptosisapoptosisDNA cross-linksDNA-protein cross-linksanticancerInhibitorinhibitorinhibit

    You might also be interested by the following products:



    Cat#
    Description
    Cond.
    Price Bef. VAT
    CSB005A
    Cusa Fast Pfu DNA Polymerase
     250U